Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease (Q24245141)

4

author given names

A

author last names

Veale

1 reference

29 October 2023

Toby J Lasserson

5

author given names

T J

author last names

Lasserson

1 reference

29 October 2023

Matthew Ming Ki Chan

6

author given names

M M

author last names

Chan

1 reference

29 October 2023

Christopher J Cates

Cochrane Database of Systematic Reviews

7

0 references

publication date

19 July 2006

0 references

published in

0 references

cites work

Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001104.PUB2

Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001104.PUB2

Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001104.PUB2

Gender does not influence the response to the combination of salmeterol and fluticasone propionate in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001104.PUB2

The addition of salmeterol 50 microg bid to anticholinergic treatment in patients with COPD: a randomized, placebo controlled trial. Chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001104.PUB2

Salmeterol & fluticasone 50 microg/250 microg bid in combination provides a better long-term control than salmeterol 50 microg bid alone and placebo in COPD patients already treated with theophylline

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001104.PUB2

Effects of regular salmeterol on lung function and exercise capacity in patients with chronic obstructive airways disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001104.PUB2

The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001104.PUB2

Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001104.PUB2

Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001104.PUB2

Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001104.PUB2

Efficacy of inhaled salmeterol in the management of smokers with chronic obstructive pulmonary disease: a single centre randomised, double blind, placebo controlled, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001104.PUB2

An empirical comparison of the St George's Respiratory Questionnaire (SGRQ) and the Chronic Respiratory Disease Questionnaire (CRQ) in a clinical trial setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001104.PUB2

Effects of formoterol and ipratropium bromide in COPD: a 3-month placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001104.PUB2

Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001104.PUB2

Salmeterol xinafoate. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001104.PUB2

Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001104.PUB2

Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001104.PUB2

Effect of salmeterol and formoterol in patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001104.PUB2

In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium : a 3-week, randomized, double-blind, within-patient, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001104.PUB2

Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001104.PUB2

A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001104.PUB2

Multicenter 1-year trial on formoterol, a new long-acting beta 2-agonist, in chronic obstructive airway disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001104.PUB2

Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001104.PUB2

The TORCH (towards a revolution in COPD health) survival study protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001104.PUB2

Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001104.PUB2

Tiotropium for stable chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001104.PUB2

Bronchodilator reversibility testing in chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001104.PUB2

Simpson's paradox and calculation of number needed to treat from meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001104.PUB2

Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001104.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001104.PUB2

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001104.PUB2

Combined corticosteroid and longacting beta-agonist in one inhaler for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001104.PUB2

Long-acting beta2-agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001104.PUB2

Assessing the minimal important difference in symptoms: a comparison of two techniques.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001104.PUB2

Impact of preventing exacerbations on deterioration of health status in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001104.PUB2

Investigating and Dealing with Publication and Other Biases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001104.PUB2

Long-term Treatment Benefits With Tiotropium in COPD Patients With and Without Short-term Bronchodilator Responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001104.PUB2

Effect of long-term treatment with salmeterol on asthma control: a double blind, randomised crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001104.PUB2

Long-acting beta2-agonists for chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001104.PUB2

7 January 2021

A comparison of the bronchodilating effects of salmeterol, salbutamol and ipratropium bromide in patients with chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001104.PUB2

7 January 2021

Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001104.PUB2

7 January 2021

The St George's Respiratory Questionnaire

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001104.PUB2

7 January 2021

A combination with clinical recommended dosages of salmeterol and ipratropium is not more effective than salmeterol alone in patients with chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001104.PUB2

7 January 2021

An overview of nine clinical trials of salmeterol in an asthmatic population

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001104.PUB2

7 January 2021

Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001104.PUB2

7 January 2021

A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001104.PUB2

7 January 2021

Qualitative aspects of exertional breathlessness in chronic airflow limitation: pathophysiologic mechanisms

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001104.PUB2

7 January 2021

Quality of life changes in COPD patients treated with salmeterol

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001104.PUB2

7 January 2021

Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001104.PUB2

7 January 2021

Salmeterol reduces dyspnea and improves lung function in patients with COPD

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001104.PUB2

7 January 2021

Efficacy of salmeterol xinafoate in the treatment of COPD

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001104.PUB2

7 January 2021